<p>
    Listing and Waitlist Management (Chronic ALD):
</p>
<p>
    Following is for individuals who may not meet traditional six-month abstinence criteria but demonstrate readiness and capacity to maintain sobriety and engage in long-term treatment.
</p>
<p>
    <strong>Eligibility Criteria:</strong>
</p>
<ul>
    <li class="ck-list-marker-bold" data-list-item-id="ee00613e39e1f7f7fe6c8a98f130d7ddc">
        <strong>Medical Inclusion Criteria:</strong>
        <ul>
            <li data-list-item-id="eccabc9875f468827e5862fad607fa0bd">
                Patients must meet existing listing criteria for liver transplantation or present with poor prognostic factors not fully reflected in the MELD score (e.g., refractory ascites). There must be no absolute contraindications to transplant. &nbsp;
            </li>
            <li data-list-item-id="e1c753cf22eab13a01c28774176be1dd9">
                Assessments incorporate validated tools such as SIPAT, HRAR, and ARRA.
            </li>
        </ul>
    </li>
    <li class="ck-list-marker-bold" data-list-item-id="e28402b07058d29b9275a238aec4152c7">
        <strong>Psychosocial Inclusion Criteria:</strong>
        <ul>
            <li data-list-item-id="e83f88716989faccbfd0bde685062bdb4">
                Patients must not meet diagnostic criteria for moderate to severe Alcohol Use Disorder (AUD) likely to cause post-transplant relapse. &nbsp;
            </li>
            <li data-list-item-id="e99b461a4f43d808060332601387d73bf">
                They must commit to alcohol abstinence and AUD treatment before and after transplant, have no more than one prior failed treatment attempt, and be free of other untreated substance use disorders or severe psychiatric illness. &nbsp;
            </li>
            <li data-list-item-id="ecf81a0e79dedc99409019340e1ad64fb">
                Stable housing, a support person, and reliable contact are required.
            </li>
            <li data-list-item-id="e70f4d7a0ad095462c65d30654af40ddd">
                All candidates undergo a thorough social work and addiction psychiatry assessment.
            </li>
        </ul>
    </li>
</ul>
<p>
    <strong>Evaluation &amp; Referral Process:&nbsp;</strong>
</p>
    <table class="table table-bordered">
        <tbody>
            <tr class="table-secondary">
                <td>
                    Stage&nbsp;
                </td>
                <td>
                    Tasks&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    <p>
                        Referral Phase &nbsp;
                    </p>
                    <p>
                        (Days 1–7)&nbsp;
                    </p>
                </td>
                <td>
                    <ul>
                        <li data-list-item-id="e1b164b6db260a97783e176c6cce5906b">
                            Referring physicians identify suitable patients, complete the transplant referral form and psychosocial questionnaire, and submit them to the transplant centre. &nbsp;
                        </li>
                        <li data-list-item-id="e816a575f15acf2eed166738183792bcb">
                            Addiction Psychiatry and the Transplant Physician review the application to determine program eligibility. Accepted patients proceed to a full assessment.&nbsp;
                        </li>
                    </ul>
                </td>
            </tr>
            <tr>
                <td>
                    <p>
                        Consultation Phase &nbsp;
                    </p>
                    <p>
                        (Days 8–16)&nbsp;
                    </p>
                </td>
                <td>
                    <ul>
                        <li data-list-item-id="eafdccb0a0bb8c402ec5bb916ceae0607">
                            Patients undergo EtG testing and are evaluated by an addiction psychiatrist and social worker. If deemed suitable from a psychosocial standpoint, they are asked (with support persons) to formally commit to abstinence and treatment. &nbsp;
                        </li>
                        <li data-list-item-id="ee99373c3c30a6750f24b69b222579d31">
                            A medical assessment follows. The listing committee then reviews the full case to determine if the patient should be listed.&nbsp;
                        </li>
                    </ul>
                </td>
            </tr>
            <tr>
                <td>
                    Waitlist Management&nbsp;
                </td>
                <td>
                    <ul>
                        <li data-list-item-id="ec58fa35ab21526e60742e72b4d69fb1f">
                            Patients are monitored monthly with Na MELD testing, EtG or CDT biomarker assessments, and psychosocial reviews. &nbsp;
                        </li>
                        <li data-list-item-id="e2a1dd363597602c008e58736e5a2acf0">
                            A first positive test leads to a hold; a second results in removal from the list. &nbsp;
                        </li>
                        <li data-list-item-id="e286b161ee00a65073de73ba93cbd57e8">
                            Ongoing relapse prevention treatment is required, with adherence tracked. &nbsp;
                        </li>
                        <li data-list-item-id="e47d4d17b4f82f2665a5c62f2317e148e">
                            Missed appointments/non-medical reasons for non-participation may result in hold/delisting.
                        </li>
                        <li data-list-item-id="efb4afa593c6c8422f78b7b6908f801a3">
                            As with all patients, breakdown in support, inability to arrive for transplant, or significant recovery may warrant status changes.&nbsp;
                        </li>
                    </ul>
                </td>
            </tr>
        </tbody>
    </table>

    <p>
    <strong>Post-Transplant Monitoring</strong>: After transplant, patients continue relapse prevention therapy if incomplete, and undergo frequent random EtG/CDT testing in year one. Toolkits are shared with referring centres. Annual assessments are conducted by the transplant team.&nbsp;
</p>